Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05209867 · ClinicalTrials.gov registry record · Phase 4
Single-cell CBD Biomarkers of Inflammation Reduction in People Living With HIV
A Phase 4 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT05209867 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 4 participants.
The verdict
NCT05209867, a Phase 4 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
People living with HIV (PLWH) are affected by comorbidities appearing to be strongly related to chronic inflammation, a condition characterizing PLWH. The investigators propose to study the effects of CBD on inflammation in PLWH, and establish the molecular role of different immune cells in this process. The investigators plan to use single cell RNA-sequencing (scRNAseq) to isolate CBD-specific cellular phenotypes from five persons with HIV who will provide blood samples before and after taking CBD.
Interventions
- DRUG CBD oil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-05-01 |
| Est. Completion | 2022-12-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05209867
The ClinicalTrials.gov registry entry for NCT05209867 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CBD oil is the first listed.
NCT05209867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05209867 about?
NCT05209867 is a clinical study titled "Single-cell CBD Biomarkers of Inflammation Reduction in People Living With HIV". People living with HIV (PLWH) are affected by comorbidities appearing to be strongly related to chronic inflammation, a condition characterizing PLWH. The investigators propose to study the effects of CBD on inflammation in PLWH, and establish the molecular role of different immune cells in this pr...
What is the current status of trial NCT05209867?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2022-05-01. Estimated completion is 2022-12-12.
What interventions are being tested in trial NCT05209867?
The interventions under investigation include: CBD oil (DRUG).
Who is sponsoring clinical trial NCT05209867?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.